Injective falls amid sustained selling pressure

Traders Union
All News
Crypto
Injective slides 8.93% to $7.28 today

Highlights

Injective secured SEC transfer agent registration, expanding regulatory-compliant service offerings for US institutional clients.
The company completed live pilots with POSCO International and LG CNS, booking over $1 billion in tokenized mortgage data and enabling pre-IPO trading for SpaceX and OpenAI.
INJ/USD trades below short- and medium-term moving averages with strong negative momentum; expected range is $6.89 to $7.66 as sellers maintain control.

Institutional adoption expands as regulatory approval meets persistent selling

Injective achieved registration as a transfer agent with the US Securities and Exchange Commission, a development that enables regulatory compliance and broadens its service capabilities for US-based institutional clients, according to FXStreet. The company also completed successful live pilots with POSCO International and LG CNS, registering over $1 billion in tokenized mortgage data and enabling pre-IPO market activity for high-profile equities such as SpaceX and OpenAI, further demonstrating institutional use of its platform. Additionally, Injective expanded its ecosystem to include 135 real-world asset markets and reported $5.3 billion in trading volume, highlighting the growth in its tokenized asset offerings, though price action has remained under broader selling pressure.

Technical momentum weakens as major moving averages are breached

On the hourly chart, INJ is trading below both the MA-20 at $7.56 and MA-50 at $7.85, while holding above the MA-200 at $5.07. Immediate resistance is identified at the Ichimoku Kijun level at $7.69. Momentum readings reflect prevailing downside pressure, with MACD and ADX confirming the dominance of sellers. The RSI stands at 30.71, nearing oversold conditions, while the CCI is already firmly within oversold territory. Stoch RSI signals are neutral. Intraday indicators, including Bull/Bear Power and the Awesome Oscillator, both corroborate the current downward momentum.

Downside risk elevated as breakout triggers cluster near support

In the short term, INJ is expected to trade within a volatility band of $6.89 to $7.66. The probability of an upward move remains very low, with downward risk dominating the scenario set. Sideways fluctuation within this corridor is the baseline expectation, while a decisive move below $6.89 could accelerate further declines, and a break above resistance at $7.69 would be required to alter short-term sentiment.

Anton Kharitonov, expert at Traders Union, sees institutional adoption and SEC registration as clear positives for Injective. However, he notes price action remains weak and technical signals are not supportive. The dominant trend is down, with no clear sign of reversal yet. "Until Injective reclaims key resistance at $7.69, I remain on the defensive and see sideways to lower as the likely outcome."

Previously it was reported that Injective was experiencing short-term selling pressure despite advancing its regulatory status and expanding its institutional offerings. The current analysis reinforces this cautious outlook, with prevailing downside momentum and oversold indicators suggesting traders should closely monitor the $6.89 support as a potential inflection point.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.